UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin

Clinical cancer research, 2011-01, Vol.17 (2), p.363-371

2011

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Gefitinib in Children With Refractory Solid Tumors: A Children’s Oncology Group Study

Journal of clinical oncology, 2005-09, Vol.23 (25), p.6172-6180

2005

Volltextzugriff (PDF)

Phase I Trial of Temozolomide and Protracted Irinotecan in Pediatric Patients with Refractory Solid Tumors

Clinical cancer research, 2004-02, Vol.10 (3), p.840-848

2004

Volltextzugriff (PDF)

Clinical Pharmacokinetics and the Impact of Genetic Polymorphism on a CYP2C19 Substrate, BMS-823778, in Healthy Subjects

Drug metabolism and disposition, 2018-03, Vol.46 (3), p.316-325

2018

Volltextzugriff (PDF)

Results of a Phase II Upfront Window of Pharmacokinetically Guided Topotecan in High-Risk Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumor

Journal of clinical oncology, 2004-08, Vol.22 (16), p.3357-3365

2004

Volltextzugriff (PDF)

Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children

Journal of neuro-oncology, 2006-02, Vol.76 (3), p.313-319

2006

Volltextzugriff (PDF)

Population Pharmacokinetic Analysis of Topotecan in Pediatric Cancer Patients

Clinical cancer research, 2007-11, Vol.13 (22), p.6703-6711

2007

Volltextzugriff (PDF)

Liquid chromatography and tandem mass spectrometry for the quantitative determination of ixabepilone (BMS-247550, Ixempra™) in human plasma: Method validation, overcoming curve splitting issues and eliminating chromatographic interferences from degradants

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2010-02, Vol.878 (5), p.525-537

2010

Volltextzugriff (PDF)

The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone: A First in Class Epothilone B Analogue in Late-Phase Clinical Development

Clinical cancer research, 2008-05, Vol.14 (9), p.2701-2709

2008

Volltextzugriff (PDF)

Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice

Cancer chemotherapy and pharmacology, 2005-12, Vol.56 (6), p.629-636

2005

Volltextzugriff (PDF)

The Importance of Pharmacokinetic Limited Sampling Models for Childhood Cancer Drug Development

Clinical cancer research, 2003-11, Vol.9 (14), p.5068-5077

2003

Volltextzugriff (PDF)

Determination of plasma topotecan and its metabolite N-desmethyl topotecan as both lactone and total form by reversed-phase liquid chromatography with fluorescence detection

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2003-02, Vol.784 (2), p.225-232

2003

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Topotecan Administered Orally Once Daily for 5 Days for 2 Consecutive Weeks to Pediatric Patients With Refractory Solid Tumors

Journal of clinical oncology, 2004-03, Vol.22 (5), p.829-837

2004

Volltextzugriff (PDF)

Physiologically‐based pharmacokinetic modelling of a CYP2C19 substrate, BMS‐823778, utilizing pharmacogenetic data

British journal of clinical pharmacology, 2018-06, Vol.84 (6), p.1335-1345

2018

Volltextzugriff (PDF)

Clinical significance of CYP2C19 polymorphisms on the metabolism and pharmacokinetics of 11β‐hydroxysteroid dehydrogenase type‐1 inhibitor BMS‐823778

British journal of clinical pharmacology, 2018-01, Vol.84 (1), p.130-141

2018

Volltextzugriff (PDF)

Novel Function of the Regulatory Subunit of Protein Kinase A: Regulation of Cytochrome c Oxidase Activity and Cytochrome c Release

Biochemistry (Easton), 1998-10, Vol.37 (40), p.14175-14180

1998

Volltextzugriff (PDF)

First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3003-3003

2022

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of intravenous epoetin alfa in children with cancer

Pediatric blood & cancer, 2006-10, Vol.47 (5), p.572-579

2006

Volltextzugriff (PDF)

Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in children

Cancer chemotherapy and pharmacology, 2006-04, Vol.57 (4), p.475-482

2006

Volltextzugriff (PDF)

Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma

Neuro-oncology (Charlottesville, Va.), 2006-04, Vol.8 (2), p.89-95

2006

Volltextzugriff (PDF)

Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC

Cancer chemotherapy and pharmacology, 2005-05, Vol.55 (5), p.433-438

2005

Volltextzugriff (PDF)

Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children

Cancer, 2005-01, Vol.103 (1), p.133-139

2005

Volltextzugriff (PDF)

Topotecan disposition in an anephric child

Journal of pediatric hematology/oncology, 2004-09, Vol.26 (9), p.596-600

2004

Volltextzugriff (PDF)

A validated enantioselective LC–MS/MS assay for quantification of a major chiral metabolite of an achiral 11-β-hydroxysteroid-dehydrogenase 1 inhibitor in human plasma: Application to a clinical pharmacokinetic study

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2016-06, Vol.1022, p.167-172

2016

Volltextzugriff (PDF)

Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: Results of a multiinstitutional study (SJHG-98)

Cancer, 2005, Vol.103 (1), p.133-139

2005

Volltextzugriff (PDF)

1 – 25 von 91

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(86)
Mit Volltextzugriff
(82)

Publikationsform

Sprache

Englisch
(91)

Erscheinungsjahr

n.n

Thema

Science & Technology
(63)
Life Sciences & Biomedicine
(62)
Humans
(55)
Male
(38)
Female
(36)
Biological And Medical Sciences
(35)
Medical Sciences
(33)
Adolescent
(27)
Adult
(23)
Child
(22)
Oncology
(19)
Pharmacology. Drug Treatments
(14)
Psychology. Psychoanalysis. Psychiatry
(13)
Psychology
(12)
Middle Aged
(11)
Psychopathology. Psychiatry
(11)
Adult And Adolescent Clinical Studies
(10)
Children
(10)
Risk Factors
(10)
Social Sciences
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin

Phase I and Pharmacokinetic Study of Gefitinib in Children With Refractory Solid Tumors: A Children’s Oncology Group Study

Phase I Trial of Temozolomide and Protracted Irinotecan in Pediatric Patients with Refractory Solid Tumors

Clinical Pharmacokinetics and the Impact of Genetic Polymorphism on a CYP2C19 Substrate, BMS-823778, in Healthy Subjects

Results of a Phase II Upfront Window of Pharmacokinetically Guided Topotecan in High-Risk Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumor

Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children

Population Pharmacokinetic Analysis of Topotecan in Pediatric Cancer Patients

Liquid chromatography and tandem mass spectrometry for the quantitative determination of ixabepilone (BMS-247550, Ixempra™) in human plasma: Method validation, overcoming curve splitting issues and eliminating chromatographic interferences from degradants

The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone: A First in Class Epothilone B Analogue in Late-Phase Clinical Development

Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice

The Importance of Pharmacokinetic Limited Sampling Models for Childhood Cancer Drug Development

Determination of plasma topotecan and its metabolite N-desmethyl topotecan as both lactone and total form by reversed-phase liquid chromatography with fluorescence detection

Phase I and Pharmacokinetic Study of Topotecan Administered Orally Once Daily for 5 Days for 2 Consecutive Weeks to Pediatric Patients With Refractory Solid Tumors

Physiologically‐based pharmacokinetic modelling of a CYP2C19 substrate, BMS‐823778, utilizing pharmacogenetic data

Clinical significance of CYP2C19 polymorphisms on the metabolism and pharmacokinetics of 11β‐hydroxysteroid dehydrogenase type‐1 inhibitor BMS‐823778

Novel Function of the Regulatory Subunit of Protein Kinase A: Regulation of Cytochrome c Oxidase Activity and Cytochrome c Release

First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation

Pharmacokinetics and pharmacodynamics of intravenous epoetin alfa in children with cancer

Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in children

Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma

Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC

Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children

Topotecan disposition in an anephric child

A validated enantioselective LC–MS/MS assay for quantification of a major chiral metabolite of an achiral 11-β-hydroxysteroid-dehydrogenase 1 inhibitor in human plasma: Application to a clinical pharmacokinetic study

Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: Results of a multiinstitutional study (SJHG-98)

Suchergebnisse filtern